Literature DB >> 11743943

The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches.

J A Lieberman1, D Perkins, A Belger, M Chakos, F Jarskog, K Boteva, J Gilmore.   

Abstract

Schizophrenia is commonly considered a neurodevelopmental disorder that is associated with significant morbidity; however, unlike other neurodevelopmental disorders, the symptoms of schizophrenia often do not manifest for decades. In most patients, the formal onset of schizophrenia is preceded by prodromal symptoms, including positive symptoms, mood symptoms, cognitive symptoms, and social withdrawal. The proximal events that trigger the formal onset of schizophrenia are not clear but may include developmental biological events and environmental interactions or stressors. Treatment with antipsychotic drugs clearly ameliorates psychotic symptoms, and maintenance therapy may prevent the occurrence of relapse. The use of atypical antipsychotic agents may additionally ameliorate the pathophysiology of schizophrenia and prevent disease progression. Moreover, if treated properly early in the course of illness, many patients can experience a significant remission of their symptoms and are capable of a high level of recovery following the initial episode. Because the clinical deterioration that occurs in schizophrenia may actually begin in the prepsychotic phase, early identification and intervention may favorably alter the course and outcome of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11743943     DOI: 10.1016/s0006-3223(01)01303-8

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  146 in total

Review 1.  Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment.

Authors:  Christine Konradi; Stephan Heckers
Journal:  Pharmacol Ther       Date:  2003-02       Impact factor: 12.310

Review 2.  Review of the operational definition for first-episode psychosis.

Authors:  Nicholas J K Breitborde; Vinod H Srihari; Scott W Woods
Journal:  Early Interv Psychiatry       Date:  2009-11       Impact factor: 2.732

Review 3.  Glutamate-mediated excitotoxicity in schizophrenia: a review.

Authors:  Eric Plitman; Shinichiro Nakajima; Camilo de la Fuente-Sandoval; Philip Gerretsen; M Mallar Chakravarty; Jane Kobylianskii; Jun Ku Chung; Fernando Caravaggio; Yusuke Iwata; Gary Remington; Ariel Graff-Guerrero
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

Review 4.  Assessment of adolescents at risk for psychosis.

Authors:  Karin Borgmann-Winter; Monica E Calkins; Kathryn Kniele; Raquel E Gur
Journal:  Curr Psychiatry Rep       Date:  2006-08       Impact factor: 5.285

Review 5.  [Early recognition and intervention for schizophrenia].

Authors:  N Mossaheb; G Wiesegger; G P Amminger; S Kasper; J Tauscher
Journal:  Nervenarzt       Date:  2006-01       Impact factor: 1.214

Review 6.  Prevention of schizophrenia: can it be achieved?

Authors:  Cheng Lee; Thomas H McGlashan; Scott W Woods
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

7.  Effectiveness of Family Intervention for Preventing Relapse in First-Episode Psychosis Until 24 Months of Follow-up: A Systematic Review With Meta-analysis of Randomized Controlled Trials.

Authors:  Miguel Camacho-Gomez; Pere Castellvi
Journal:  Schizophr Bull       Date:  2020-01-04       Impact factor: 9.306

8.  Cognition in young schizophrenia outpatients: comparison of first-episode with multiepisode patients.

Authors:  Yoram Braw; Yuval Bloch; Shlomo Mendelovich; Gideon Ratzoni; Gilad Gal; Hagai Harari; Asaf Tripto; Yechiel Levkovitz
Journal:  Schizophr Bull       Date:  2007-11-05       Impact factor: 9.306

9.  Imaging frontostriatal function in ultra-high-risk, early, and chronic schizophrenia during executive processing.

Authors:  Rajendra A Morey; Seniha Inan; Teresa V Mitchell; Diana O Perkins; Jeffrey A Lieberman; Aysenil Belger
Journal:  Arch Gen Psychiatry       Date:  2005-03

10.  Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

Authors:  Taishiro Kishimoto; Alfred Robenzadeh; Claudia Leucht; Stefan Leucht; Koichiro Watanabe; Masaru Mimura; Michael Borenstein; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2012-12-17       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.